Abstract
The standard treatment for patients with locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT), but surgical resection following induction CRT can extend overall survival in a select population. However, patients who survive longer are at risk of developing a second primary cancer (SPC). This is the first report to determine the incidence of SPC in survivors with LA-NSCLC after trimodal therapy. Between October 1997 and October 2013, 112 Stage III NSCLC patients underwent trimodal therapy in our hospital. The 5-year overall survival rate was 71.8%. SPC developed in 10 of the 112 patients 0.60-15.0 (median 5.49) years after initiating CRT. The observed incidence of SPC was 1.8 per 100 patient-years. Although trimodal therapy can prolong patient survival, the estimated incidence of SPC does not increase. A large prospective study with a longer follow-up time is required to determine the effects of trimodal therapy, including the development of SPC.
| Original language | English |
|---|---|
| Pages (from-to) | 287-290 |
| Number of pages | 4 |
| Journal | Japanese Journal of Clinical Oncology |
| Volume | 48 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 1 2018 |
Fingerprint
Keywords
- Cancer survivor
- Chemoradiotherapy
- Non-small-cell lung cancer
- Second primary cancer
- Surgical resection
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
- Cancer Research
Cite this
Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery. / Makimoto, Go; Kubo, Toshio; Oze, Isao; Oohashi, Kadoaki; Hotta, Katsuyuki; Tabata, Masahiro; Sou, Junichi; Toyooka, Shinichi; Katsui, Kuniaki; Takigawa, Nagio; Tanimoto, Mitsune; Kiura, Katsuyuki.
In: Japanese Journal of Clinical Oncology, Vol. 48, No. 3, 01.03.2018, p. 287-290.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery
AU - Makimoto, Go
AU - Kubo, Toshio
AU - Oze, Isao
AU - Oohashi, Kadoaki
AU - Hotta, Katsuyuki
AU - Tabata, Masahiro
AU - Sou, Junichi
AU - Toyooka, Shinichi
AU - Katsui, Kuniaki
AU - Takigawa, Nagio
AU - Tanimoto, Mitsune
AU - Kiura, Katsuyuki
PY - 2018/3/1
Y1 - 2018/3/1
N2 - The standard treatment for patients with locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT), but surgical resection following induction CRT can extend overall survival in a select population. However, patients who survive longer are at risk of developing a second primary cancer (SPC). This is the first report to determine the incidence of SPC in survivors with LA-NSCLC after trimodal therapy. Between October 1997 and October 2013, 112 Stage III NSCLC patients underwent trimodal therapy in our hospital. The 5-year overall survival rate was 71.8%. SPC developed in 10 of the 112 patients 0.60-15.0 (median 5.49) years after initiating CRT. The observed incidence of SPC was 1.8 per 100 patient-years. Although trimodal therapy can prolong patient survival, the estimated incidence of SPC does not increase. A large prospective study with a longer follow-up time is required to determine the effects of trimodal therapy, including the development of SPC.
AB - The standard treatment for patients with locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT), but surgical resection following induction CRT can extend overall survival in a select population. However, patients who survive longer are at risk of developing a second primary cancer (SPC). This is the first report to determine the incidence of SPC in survivors with LA-NSCLC after trimodal therapy. Between October 1997 and October 2013, 112 Stage III NSCLC patients underwent trimodal therapy in our hospital. The 5-year overall survival rate was 71.8%. SPC developed in 10 of the 112 patients 0.60-15.0 (median 5.49) years after initiating CRT. The observed incidence of SPC was 1.8 per 100 patient-years. Although trimodal therapy can prolong patient survival, the estimated incidence of SPC does not increase. A large prospective study with a longer follow-up time is required to determine the effects of trimodal therapy, including the development of SPC.
KW - Cancer survivor
KW - Chemoradiotherapy
KW - Non-small-cell lung cancer
KW - Second primary cancer
KW - Surgical resection
UR - http://www.scopus.com/inward/record.url?scp=85043472546&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043472546&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyy003
DO - 10.1093/jjco/hyy003
M3 - Article
VL - 48
SP - 287
EP - 290
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
SN - 0368-2811
IS - 3
ER -